← All trials
NCT07145645
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2025
- Primary completion
- Sep 30, 2027
- Completion date
- Mar 31, 2028
- First posted
- Aug 28, 2025
- Last posted
- Aug 28, 2025
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CalgaryLead sponsor
- University of CalgaryOfficial
- Hamilton Health Sciences CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.